Recent advances in pharmacological treatment of type 2 diabetes mellitus

DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long term complications in insulin-dependent diabetes mellitus.N Engl J Med. 1993;329:977–986. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study.Diabetes Res Clin Pract. 1995;28:103–117. Klein R, Klein BEK, Moss SE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. The relationship of C-peptide to the incidence and progression of diabetic retinopathy.Diabetes. 1995;44:796–801. Abraira C, Colwell JA, Nuttal FQ, et al for the VA CSDM Group. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes (VA CSDM): results of the feasibility trial.Diabetes Care. 1995;18:1113–23. Turner R (UKPDS Group). Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).Lancet. 1998;352:837–853. American Diabetes Association. Position statement on the standards of medical care for patients with diabetes mellitus.Diabetes Care. 1998;21(suppl 1):S23-S31. American Diabetes Association. Nutritional recommendations and principles for people with diabetes mellitus.Diabetes Care. 1997;20(suppl 1):14–17. Rosenstock J, Samols E, Muchmore DB, Schneider J, et al. Glimepiride, and a new once daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients.Diabetes Care. 1996;19:1194–1199. Draeger E. Clinical profile of glimepiride.Diabetes Res Clin Pract. 1995;28(suppl):S139–146. Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents: the Glimepiride Protocol 201 Study Group.Diabetes Care. 1996;19:849–856. Malaisse WJ. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family.Horm Metab Res. 1995;27:263. Moses R, Slobodniuk R, Wollongong, et al. Additional treatment with repaglinide provides significant improvement in glycemic control in NIDDM patients poorly controlled on metformin.Diabetologia. 1997;40(suppl 1):A322. Wolffenbuttel BHR. Effects of a new oral hypoglycemic agent, repaglinide, on metabolic control in sulfonylurea-treated agents with NIDDM.Eur J Clin Pharmacol. 1993;45:113. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type 2 diabetes mellitus.N Engl J Med. 1998;338:867–872. Wright AD, Cull CA, Holman RR, Turner RC. UKPDS 28: A randomized trial of early addition of metformin in sulfonylurea-treated type 2 diabetes.Diabetes Care. 1998;21:87–92. Wilson TM, Cobb JE, Cowan DJ, et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the anti-hyperglycemic activity of the thiazolidinediones.J Med Chem. 1996;39:665–68. Schwartz S, Raskin P, Fonseca V, et al. Effect of troglitazone in insulin-treated patients with type 2 diabetes.N Engl J Med. 1998;338:861–866. Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effect of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial.Ann Intern Med. 1998;128:176–185. Fonseca V, Valiquett TR, Whitcomb R. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study.J Clin Endocrinol Metab. 1998;83:369–376. Fonseca V, Reynolds T, Hemphill D, et al. Effect of troglita-zone on fibrinolysis and coagulation [abstract].Diabetes. 1997;46:93A. Rezulin physician’s monograph. Morris Plains, NJ: Parke-Davis; 1997. Buse J, Hart K, Minasi L. The Protect Study: final results of a large multi-center post-marketing study in patients with type 2 diabetes: Precose resolution of optimal titration to enhance current therapies.Clin Ther. 1998;20:257–269. Soonthornpun S, Rattarasam C, Thamprasit A, Leetanaporro K. Effect of acarbose in treatment of type 2 diabetes mellitus: a double-blind, crossover, placebo-controlled trial.J Med Assoc Thai. 1998;81:195–200. Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of post-prandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment.Diabetes. 1997;46:265–270. Trautmann ME, Attanasio A, Schulze-Schleppinghoff B, et al. Blood sugar control during treatment with an insulin-analog [abstract].Diabetologia. 1993;36(suppl A):155.